Recombinant human insulin (HEC Pharm) |
|
BLA Filing |
HEC Pharm, Yichang HEC Changjiang Pharmaceutical |
Diabetes |
Details
|
INS-061 |
INS-061; HS-061 |
IND Filing |
Shanghai Hengrui |
Diabetes |
Details
|
Insulin icodec |
148-0287-A; Insulin-287; LAI-287; Long-acting basal insulin analogue; Long-acting-insulin-287; NN-1436; NN-1956; NNC-0148-0000-0287; NNC0148-0287 C; OI-287GT |
Phase Ⅲ |
Novo Nordisk |
Type 2 diabetes |
Details
|
Insulin glargine biosimilar (YiChang HEC ChangJiang Pharmaceutical) |
|
Phase Ⅲ |
HEC Pharm, Lannett |
Diabetes |
Details
|
Stem cell therapy (RejuvaCell) |
|
Phase Not Specified |
RejuvaCell |
Type 2 diabetes |
Details
|
Insulin lispro/Insulin glargine |
|
Phase Ⅱ |
Adocia |
Type 1 diabetes, Type 2 diabetes |
Details
|
Insulin detemir biosimilar (Tonghua Dongbao Pharmaceutical) |
|
Phase Ⅰ |
Tonghua Dongbao Pharmaceutical |
Diabetes |
Details
|
Insulin prandial injectable (Albireo Pharma) |
VIAject-25; VIAject-7 |
BLA Filing |
Albireo |
Type 1 diabetes, Diabetes, Type 2 diabetes |
Details
|
Insulin oral (Emisphere Technologies) |
|
Phase Ⅱ |
Emisphere Technologies |
Type 2 diabetes |
Details
|
Insulin aspart biosimilar (Gan & Lee) |
|
BLA Filing |
Gan & Lee Biotech |
Type 1 diabetes, Type 2 diabetes |
Details
|
NN-1406 |
NN-1406; NNC0143-0406; NNC0143-0406 A; PI-406 |
Phase Ⅰ |
Novo Nordisk |
Type 1 diabetes, Type 2 diabetes |
Details
|
Insulin glargine biosimilar(Shandong New Time Pharmaceutical) |
|
BLA Filing |
Lunan Pharmaceutical Group Corporatio |
Diabetes |
Details
|
Insulin (Oramed Pharmaceuticals) |
ORMD-0801 |
Phase Ⅱ |
Oramed Pharmaceuticals, Hefei Tianhui Incubator of Technologies |
Type 1 diabetes, Type 2 diabetes |
Details
|
Bacitracin/Tranexamic acid |
IPI-120 |
Preclinical |
Imprimis Pharmaceuticals |
wound, Wound infections |
Details
|
Recobinant human proinsulin C peptide (Shanghai Newsummit/Shanghai Yizhong) |
|
Phase Ⅰ |
Shanghai Newsummit Biopharma |
Diabetic nephropathy |
Details
|
Insulin lispro (Diasome Pharmaceuticals) |
|
Phase Ⅱ |
Diasome Pharmaceuticals |
Type 1 diabetes |
Details
|
Transdermal insulin patch (Dermisonics) |
|
Phase Ⅰ |
Dermisonics, Encapsulation Systems, Transdermal Global |
Diabetes |
Details
|
Insulin biosimilar (Hefei Tianmai Biotechnology) |
|
Phase Ⅲ |
Hefei Tianmai Biotechnology |
Diabetes |
Details
|
Insulin adjustable basal (Biodel) |
BIOD-809 |
Phase Ⅰ |
Albireo |
Diabetes |
Details
|
Transdermal insulin patches (SK Chemicals) |
|
Phase Ⅲ |
SK Chemicals |
Type 1 diabetes |
Details
|
Insulin glargine biosimilar (Wanbang Biochemical) |
|
Phase Ⅲ |
Wanbang Biopharmaceuticals |
Type 2 diabetes |
Details
|
DM199 |
DM-199; DM-99 |
Phase Ⅱ |
DiaMedica |
Stroke, Type 2 diabetes, Chronic kidney disease |
Details
|
PE-0139 |
PE-0139 |
Phase Ⅱ |
PhaseBio |
Type 2 diabetes |
Details
|
Ultra-rapid-acting insulin analogue (Albireo Pharma) |
BIOD-238 |
Phase Ⅰ |
Albireo |
Type 1 diabetes |
Details
|
Insulin transdermal (TransPharma Medical) |
|
Phase Not Specified |
TransPharma Medical |
Type 1 diabetes, Type 2 diabetes |
Details
|
Transbuccal insulin (MidaSol) |
MSRX-301; MSL-001; MTD-101 |
Phase Ⅱ |
Midatech, Aquestive Therapeutics |
Type 1 diabetes |
Details
|
Basal insulin peglispro |
LY-2605541,LY2605541 |
Phase Ⅲ |
Lilly, Boehringer Ingelheim |
Type 1 diabetes, Type 2 diabetes |
Details
|
Insulin mouth rinse (EastGate Biotech) |
|
Phase Ⅲ |
Eastgate Biotech, Genome Pharmaceuticals |
Type 1 diabetes, Type 2 diabetes, Alzheimer's disease (AD) |
Details
|
Recombinant human insulin biosimilar (Rechon Life Sciences) |
|
Phase Ⅲ |
Rechon Life Science |
Type 1 diabetes |
Details
|
KW-2450 |
KW-2450 |
Phase Ⅱ |
Kyowa Hakko Kirin |
Breast cancer |
Details
|
Recombinant insulin aspart biosimilar (Biogenomics) |
|
Phase Ⅲ |
Biogenomics |
Type 2 diabetes |
Details
|
Ultra fast-acting insulin analogue |
BC-106-Insulin-Lispro; BC-222-Insulin-Lispro |
Phase Ⅲ |
Adocia, Lilly, Tonghua Dongbao Pharmaceutical |
Type 1 diabetes, Type 2 diabetes |
Details
|
Insulin receptor-regulating antibodies (XOMA) |
X-129; XMet program; XMetA; XMetD;XMetS; XOMA-129 |
Preclinical |
Xoma |
Diabetes, Hypoglycemia |
Details
|
SAR-161271 |
SAR 161271,SAR-161271,SAR161271 |
Phase Ⅱ |
Sanofi |
Type 1 diabetes |
Details
|
NN-344 |
NN-344 |
Phase Ⅰ |
Novo Nordisk A/S |
Type 1 diabetes, Type 2 diabetes |
Details
|
Insulin inhalation (Aerogen) |
|
Phase Ⅱ |
Nektar |
Diabetes |
Details
|
Insulin rectal (Oramed Pharmaceuticals) |
ORMD-0802 |
Phase Ⅰ |
Oramed Pharmaceuticals |
Type 1 diabetes |
Details
|
Oral insulin (Purede) |
|
Phase Not Specified |
Puredel |
Diabetes |
Details
|
Insulin glargine biosimilar (Tonghua Dongbao Pharmaceutical) |
|
BLA Filing |
Tonghua Dongbao Pharmaceutical |
Diabetes |
Details
|
Human insulin biosimilar (Marvel Lifesciences) |
|
BLA Filing |
Marvel LifeSciences Private |
Diabetes |
Details
|
Fast-acting human insulin (Adocia) |
BioChaperone-222; Hinsbet-U500 |
Phase Ⅱ |
Adocia |
Type 1 diabetes |
Details
|
Recombinant human insulin (Nutrinia) |
NTRA-9620,NTRA 9620,NTRA9620 |
Phase Ⅲ |
Nutrinia |
Short bowel syndrom |
Details
|
Insulin lispro biosimilar (Valin Technologies) |
|
Preclinical |
Valin Technologies |
Diabetes |
Details
|
Insulin polysialic (Xenetic Biosciences) |
SYN-20090110-RU; SYN-20090510-RU |
Phase Ⅰ |
Lipoxen Technologies, SynBio, Xenetic Biosciences |
Type 1 diabetes, Central nervous system disorders, Type 2 diabetes |
Details
|
Insulin biosimilars (Bioton) |
|
Phase Not Specified |
Bioton |
Diabetes |
Details
|
Insulin inhalation (Andaris) |
|
Phase Ⅰ |
Elan Corporation |
Diabetes |
Details
|
Oral insulin-338-C10 |
Insulin-338-GIPET-I; LAI-338; NN-1438; NN-1953; NNC0123-0338; OI-338GT; Oral insulin 338 C10 |
Phase Ⅱ |
Novo Nordisk, Merrion Pharmaceuticals |
Type 1 diabetes, Type 2 diabetes |
Details
|
Ultra-rapid-acting insulin analogues (Albiero Pharma) |
BIOD-250 |
Phase Ⅰ |
Albireo |
Type 1 diabetes |
Details
|
Dulaglutide/Basal insulin Fc |
|
Phase Ⅰ |
Lilly |
Diabetes |
Details
|
Linsitinib |
ASP-7487; OSI-906; OSI-906AA,ASP7487,OSI906,OSI906AA |
Phase Ⅲ |
Astellas, National Cancer Institute |
Adrenocortical carcinoma |
Details
|
Insulin biosimilar (Valin Technologies) |
Van-101,Van 101,Van101 |
Phase Ⅲ |
Valin Technologies |
Diabetes |
Details
|
EX-1000 |
EX1000,EX 1000 |
Phase Ⅱ |
Novo Nordisk |
Type 2 diabetes |
Details
|
Insulin human (Pfizer) |
HMR 4006 |
Withdrawn |
Pfizer, Nektar |
Diabetes |
Details
|
Insulin aspart biosimilar (Zhuhai United Laboratories) |
|
BLA Filing |
United Laboratories |
Type 1 diabetes, Type 2 diabetes |
Details
|
INS-068 |
INS-068,INS068; INS 068 |
Phase Ⅰ |
Jiangsu Hengrui Medicine, Chengdu Shengdi, Shanghai Hengrui |
Type 1 diabetes, Type 2 diabetes |
Details
|
Insulins (Halozyme) |
Analog insulin-PH20; Aspart-PH20;Insulin-PH20; Lispro-PH20; rHuPH20/insulin |
Phase Ⅱ |
Halozyme Therapeutics |
Type 1 diabetes, Type 2 diabetes |
Details
|
Intranasal insulin (Johns Hopkins University) |
|
Phase Ⅱ |
Johns Hopkins University |
HIV-associated neurocognitive disorder, Multiple sclerosis (MS) |
Details
|
Insulin (Altea Therapeutics) |
AT-1391 |
Phase Ⅱ |
Nitto Denko |
Type 1 diabetes, Type 2 diabetes |
Details
|
Human insulin/EDTA/Citrate/Magnesium sulfate (Biodel) |
BIOD-123 |
Phase Ⅱ |
Albireo |
Type 1 diabetes |
Details
|
MK-2640 |
MK-2640,MK2640,MK 2640 |
Phase Ⅰ |
Merck Sharp & Dohme |
Type 1 diabetes |
Details
|
recombinant human insulin |
CKD-401,CKD 401,CKD401 |
Phase Ⅲ |
Chong Kun Dang |
Diabetes |
Details
|
Insulin glargine biosimilar (Valin Technologies) |
|
Phase Ⅰ |
Valin Technologies |
Diabetes |
Details
|
AB-101 (Rezolute) |
AB-101 |
Phase Ⅰ |
IPR Pharmaceuticals, Rezolute, Xoma |
Type 1 diabetes |
Details
|
重组赖精胰岛素(合肥天麦) |
|
Phase Ⅲ |
Hefei Tianmai Biotechnology |
Diabetes |
Details
|
Insulin inhalation (MAP Pharmaceuticals) |
MAP-0001 |
Phase Ⅰ |
Allergan |
Type 1 diabetes, Type 2 diabetes |
Details
|
Insulin biosimilar (University of Montreal Health Centre) |
|
Phase Ⅰ |
University of Montreal Health Centre |
Glaucoma |
Details
|
Insulin oral (Diabetology) |
DTY-001 |
Phase Ⅱ |
Diabetology Ltd, USV |
Type 1 diabetes, Type 2 diabetes |
Details
|
NN-1954 (Novo Nordisk) |
NN-1954 |
Phase Ⅰ |
Novo Nordisk |
Type 1 diabetes, Type 2 diabetes |
Details
|
Concentrated ultra-rapid-acting insulin (Albireo Pharma) |
BIOD-531 |
Phase Ⅱ |
Albireo |
Type 2 diabetes |
Details
|
Insulin glargine biosimilar (Geropharm) |
|
Phase Ⅲ |
GEROPHARM |
Type 1 diabetes, Type 2 diabetes |
Details
|
NKTR-034 |
NKTR-034 |
Phase Ⅰ |
Nektar |
Diabetes |
Details
|
BetaRx |
|
Phase Ⅱ |
Vivorx Pharmaceuticals |
Diabetes |
Details
|
HM-12460A |
HM-12470; HM-12470A; SAR-440067 |
Phase Ⅰ |
Hanmi |
Type 1 diabetes, Type 2 diabetes |
Details
|
Insulin inhaled (Translational Research) |
|
Phase Ⅰ |
Translational Research Ltd |
Type 1 diabetes |
Details
|
Insulin inhalation (Abbott Laboratories) |
KI-02212; KI-02-212 |
Phase Ⅱ |
Abbott |
Diabetes |
Details
|
Ultra fast-acting insulin lispro biosimilar (Perosphere) |
URAL |
Phase Ⅰ |
Perosphere |
Type 1 diabetes |
Details
|
AI-401 |
AI-401 |
Phase Ⅲ |
The National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes |
Details
|
Pegylated recombinant human insulin (Chongqing Fujin Biomedical) |
|
Phase Ⅰ |
Chongqing Fujin Biomedical |
Diabetes |
Details
|
Insulin lispro biosimilar (Wanbang Biopharma) |
|
Phase Ⅲ |
Wanbang Biopharmaceuticals |
Diabetes |
Details
|
CLX-0901 |
CLX 0901 |
Phase Ⅱ |
Theracos |
Type 2 diabetes |
Details
|
Insulin aspart biosimilar (Geropharm) |
GP-40071; GP-40081 |
Phase Ⅲ |
GEROPHARM |
Diabetes |
Details
|
Alirinetide |
GM-6; GM-600; GM-602; GM-603; GM-604; GM-605; GM-606; GM-607; GM-608; GM-609 |
Phase Ⅱ |
Genervon |
Amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Ischemic stroke |
Details
|
HM-12470 |
HM-12470A; SAR-440067; LAPS Insulin 115 |
Phase Ⅰ |
Hanmi, Sanofi |
Type 1 diabetes, Type 2 diabetes |
Details
|
Insulin inhalation (Lilly/Dura Pharmaceuticals) |
|
Phase Ⅱ |
Dura Pharmaceuticals, Lilly |
Type 1 diabetes, Type 2 diabetes |
Details
|
Insulin 320 |
OI320GT; NN-1957 |
Phase Ⅰ |
Novo Nordisk |
Type 2 diabetes |
Details
|
Insulin aspart biosimilar (Biocon/Mylan) |
MYL-1601D |
Phase Ⅲ |
Biocon, Mylan |
Type 1 diabetes |
Details
|
Semaglutide/Insulin 287 |
NNC0148-0287sema |
Phase Ⅰ |
Novo Nordisk |
Type 2 diabetes |
Details
|
Recombinant human insulin (Eastgate Biotech) |
EGP-1214,EGP1214,EGP 1214 |
Phase Not Specified |
Eastgate Biotech |
Type 2 diabetes, Prediabetes |
Details
|
XOMA-358 |
XOMA-358; XOMA-247; XPA.15.247 |
Phase Ⅱ |
Xoma |
Hyperinsulinaemia, Hypoglycemia |
Details
|
Insulin inhaled (Coremed) |
|
Phase Ⅰ |
CoreMed, Wanbang Biopharmaceuticals, Fosun Pharma |
Diabetes |
Details
|
MBL protein (Bridge BioResearch) |
|
Phase Ⅰ |
Bridge BioResearch |
Type 2 diabetes |
Details
|
Insulin (Coremed) |
|
Phase Ⅰ |
CoreMed |
Diabetes |
Details
|
Insulin intranasal (Marina Biotech) |
|
Phase Ⅱ |
Marina Biotech, Autotelic |
Type 2 diabetes |
Details
|
NN-1952 |
NN-1952 |
Phase Ⅰ |
Novo Nordisk, Merrion Pharmaceuticals |
Diabetes |
Details
|
Basal insulin Fc (Eli Lilly) |
|
Phase Ⅰ |
Lilly |
Diabetes |
Details
|
Insulin aspart biosimilar (Tonghua Dongbao Pharmaceutical) |
|
Phase Ⅲ |
Tonghua Dongbao Pharmaceutical |
Diabetes |
Details
|
Insulin inhalation (Dong Sung/Biocon) |
|
Phase Ⅱ |
Biocon BioPharmaceuticals, DongSung Pharm |
Type 1 diabetes |
Details
|
Insuman U-400 |
|
BLA Filing |
Sanofi |
Type 1 diabetes |
Details
|
AKP-11 |
AKP-11,AKP11 |
Phase Ⅱ |
Akaal Pharma |
Plaque psoriasis |
Details
|
Insulin oral (Provalis) |
|
Phase Ⅱ |
Provalis |
Type 1 diabetes, Type 2 diabetes |
Details
|
Insulin (transoral) (Noven Pharmaceuticals) |
|
Phase Ⅰ |
Hisamitsu Pharmaceutical |
Type 1 diabetes |
Details
|
NP-01 (Medesis Pharma SA) |
NP01 |
Phase Ⅰ |
Medesis Pharma SA |
Type 2 diabetes |
Details
|
Oral insulin (Orin Pharmaceuticals) |
|
Phase Ⅱ |
Orin Pharmaceuticals |
Type 2 diabetes |
Details
|
BIOD-125 (Biodel) |
|
Phase Ⅰ |
Albireo |
Type 1 diabetes |
Details
|
Hepatoselective insulin (BTG/King's College London) |
|
Phase Ⅰ |
King's College London, BTG plc |
Type 1 diabetes |
Details
|